Speedel Group: Strings Attached? No Problem
Executive Summary
Speedel Group sets itself apart from many in-licensing companies by offering partners a call-back option on development projects. This, plus its tight focus on renin inhibition and Big Pharma savvy management have allowed the group to build a pipeline. Critics say the model restricts Speedel's upside. But the success of its first project, Novartis' Phase III SPP100, and one of Europe's largest private financings of 2003 suggest the group has a strong chance of proving them wrong.
You may also be interested in...
Synosis: the Financial Leverage of Translational Medicine
Biotech investors have struggled with the fact that it takes take years, hundreds of millions of dollars, and widely varying sets of expertise to create a product. For Synosis, the answer is translational medicine: it starts life with nine compounds from three European companies, aiming to figure out the best indications and dosing for each, prove them through Phase II, and then out-license them.
IPO Failures Can Set Up Biotech Successes
Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.
Product Focus Takes Europe Back to Its Roots
More of Europe's VCs have found the product religion, abandoning platforms. Now they say they need two things to manage product risk: larger portfolios of drugs than most in-licensing companies can create and management teams which can both develop drugs and exercise commercial discipline in choosing programs to bring forward, alone or with a partner. Spin-outs, which provide both management and a relatively large group of projects, are increasingly the European start-up method of choice.